From New Mechanisms to New Standards of Care
Focusing on Improving Patient Outcomes in Infectious Diseases
Latest News
News / 10 Jan 2019
Completion of $25 million Subscription
News / 04 Jan 2019
Result of General Meeting
News / 17 Dec 2018
Proposed Subscription to Raise $25.0 million and Notice of General Meeting
We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
Chief Executive Officer
For Investors
Visit our dedicated section for investors that contains the latest available financial and regulatory information
Latest Event
Listen to our sponsored KOL event on antibiotic stewardship hosted by Slingshot Insights
Our Discuva Platform
Our technology platform is at the heart of our research to develop new mechanism antibiotics